[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsRNU0CyyMYDKyOz0DozLxQR7qXLZeuZBO8GK3zi41bI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":57,"rows":64},"University College Dublin",[4],111,false,29,3,52078,5,90,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Obesity",4,{"name":18,"count":16},"Aging",{"name":20,"count":16},"Appetite Loss",{"name":22,"count":9},"Sustainable Healthy Diet",{"name":24,"count":9},"Personalised Nutrition",{"name":26,"count":9},"Exercise",{"name":28,"count":9},"Sarcopenia",{"name":30,"count":9},"Pain",[32,37,42,47,52],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT07439978","Encapsulated Probiotics & Gut Microbiota","2026-06","probiotic containing L.rhamnosus R0011 strain",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07510282","Probiotic Delivered to the Small Intestine Changes Microbiota","2026-08","Probiotic containing L.rhamnosus R0011 strain",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07559643","The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.","2026-08-01","Tinzaparin",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07457424","Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","2026-08-31","semaglutide 1 mg weekly",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04174755","Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV","2027-01","Semaglutide Injectable Product",[58,59,60,61,62,63],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[65,98,124,142,165,188,227,252,278,305,323,348,377,395,421,439,463,489,527,554,572,590,608,635,661,679,706],{"intervention":41,"totalTrials":66,"cells":67},2,{"EARLY_PHASE1":68,"PHASE1":71,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":96},{"trials":69,"activeCount":70},[],0,{"trials":72,"activeCount":66,"soonestReadout":35},[73,83],{"nctId":38,"briefTitle":39,"status":74,"phases":75,"primaryCompletion":40,"completion":76,"start":77,"enrollment":78,"conditions":79,"interventions":82},"NOT_YET_RECRUITING",[59],"2026-12","2026-04-15",25,[80,81],"Colonization, Asymptomatic","Colonization",[41],{"nctId":33,"briefTitle":34,"status":74,"phases":84,"primaryCompletion":35,"completion":40,"start":85,"enrollment":86,"conditions":87,"interventions":89},[59],"2026-04",50,[80,88],"Colonisation",[36],{"trials":91,"activeCount":70},[],{"trials":93,"activeCount":70},[],{"trials":95,"activeCount":70},[],{"trials":97,"activeCount":70},[],{"intervention":46,"totalTrials":99,"cells":100},1,{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":111},{"trials":102,"activeCount":70},[],{"trials":104,"activeCount":70},[],{"trials":106,"activeCount":70},[],{"trials":108,"activeCount":70},[],{"trials":110,"activeCount":70},[],{"trials":112,"activeCount":99,"soonestReadout":45},[113],{"nctId":43,"briefTitle":44,"status":74,"phases":114,"primaryCompletion":45,"completion":115,"start":45,"enrollment":116,"conditions":117,"interventions":122},[63],"2026-12-01",180,[118,119,120,121],"Bariatric Surgery","Anti-Xa Activity","VTE (Venous Thromboembolism)","Obesity & Overweight",[46,123],"enoxaparin",{"intervention":123,"totalTrials":99,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":127,"activeCount":70},[],{"trials":129,"activeCount":70},[],{"trials":131,"activeCount":70},[],{"trials":133,"activeCount":70},[],{"trials":135,"activeCount":70},[],{"trials":137,"activeCount":99,"soonestReadout":45},[138],{"nctId":43,"briefTitle":44,"status":74,"phases":139,"primaryCompletion":45,"completion":115,"start":45,"enrollment":116,"conditions":140,"interventions":141},[63],[118,119,120,121],[46,123],{"intervention":56,"totalTrials":99,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":145,"activeCount":70},[],{"trials":147,"activeCount":70},[],{"trials":149,"activeCount":70},[],{"trials":151,"activeCount":70},[],{"trials":153,"activeCount":70},[],{"trials":155,"activeCount":99,"soonestReadout":55},[156],{"nctId":53,"briefTitle":54,"status":157,"phases":158,"primaryCompletion":55,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":164},"RECRUITING",[63],"2027-07","2022-06-22",80,[15,163],"HIV-1-infection",[56],{"intervention":51,"totalTrials":99,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":168,"activeCount":70},[],{"trials":170,"activeCount":70},[],{"trials":172,"activeCount":70},[],{"trials":174,"activeCount":70},[],{"trials":176,"activeCount":70},[],{"trials":178,"activeCount":99,"soonestReadout":50},[179],{"nctId":48,"briefTitle":49,"status":180,"phases":181,"primaryCompletion":50,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"ACTIVE_NOT_RECRUITING",[],"2027-01-31","2022-02-17",140,[186,121],"Metabolic Disease",[51],{"intervention":189,"totalTrials":66,"cells":190},"Dexamethasone",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":210,"NA":225},{"trials":192,"activeCount":70},[],{"trials":194,"activeCount":70},[],{"trials":196,"activeCount":70},[],{"trials":198,"activeCount":70},[199],{"nctId":200,"briefTitle":201,"status":202,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"NCT02936427","Effects and Dose Response of Dexamethasone on Intercostal Blocks With Bupivicaine in Post Thoracic Surgery Patients","UNKNOWN",[61],"2017-12","2018-03","2016-07",60,[30],[189],{"trials":211,"activeCount":70},[212],{"nctId":213,"briefTitle":214,"status":215,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":223},"NCT03698630","Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children","COMPLETED",[62],"2012-07-13","2011-07-06",250,[221,222],"Asthma","Acute Asthma",[224,189],"Prednisolone Sodium Phosphate",{"trials":226,"activeCount":70},[],{"intervention":228,"totalTrials":99,"cells":229},"Golimumab",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":250},{"trials":231,"activeCount":70},[],{"trials":233,"activeCount":70},[],{"trials":235,"activeCount":70},[],{"trials":237,"activeCount":70},[],{"trials":239,"activeCount":70},[240],{"nctId":241,"briefTitle":242,"status":202,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},"NCT02687724","Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis",[62],"2020-02","2016-06",136,[248],"Colitis",[228],{"trials":251,"activeCount":70},[],{"intervention":253,"totalTrials":99,"cells":254},"Fampridine",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":276},{"trials":256,"activeCount":70},[],{"trials":258,"activeCount":70},[],{"trials":260,"activeCount":70},[],{"trials":262,"activeCount":70},[],{"trials":264,"activeCount":70},[265],{"nctId":266,"briefTitle":267,"status":215,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":275},"NCT02208050","A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS",[62],"2016-02-16","2014-02-21",64,[273,274],"Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis",[253],{"trials":277,"activeCount":70},[],{"intervention":279,"totalTrials":99,"cells":280},"Alendronate",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":303},{"trials":282,"activeCount":70},[],{"trials":284,"activeCount":70},[],{"trials":286,"activeCount":70},[],{"trials":288,"activeCount":70},[],{"trials":290,"activeCount":70},[291],{"nctId":292,"briefTitle":293,"status":294,"phases":295,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT02322099","Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","TERMINATED",[62],"2019-09","2016-05",53,[300],"Bone Demineralization",[279,302],"Tenofovir disoproxil",{"trials":304,"activeCount":70},[],{"intervention":302,"totalTrials":99,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":70},[],{"trials":310,"activeCount":70},[],{"trials":312,"activeCount":70},[],{"trials":314,"activeCount":70},[],{"trials":316,"activeCount":70},[317],{"nctId":292,"briefTitle":293,"status":294,"phases":318,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":319,"interventions":320},[62],[300],[279,302],{"trials":322,"activeCount":70},[],{"intervention":324,"totalTrials":99,"cells":325},"dolutegravir\u002Fabacavir\u002Flamivudine",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":346},{"trials":327,"activeCount":70},[],{"trials":329,"activeCount":70},[],{"trials":331,"activeCount":70},[],{"trials":333,"activeCount":70},[],{"trials":335,"activeCount":70},[336],{"nctId":337,"briefTitle":338,"status":294,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT02659761","Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs",[62],"2021-09","2016-11",33,[344],"Human Immunodeficiency Virus",[324],{"trials":347,"activeCount":70},[],{"intervention":349,"totalTrials":99,"cells":350},"Low dose aspirin",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":375},{"trials":352,"activeCount":70},[],{"trials":354,"activeCount":70},[],{"trials":356,"activeCount":70},[],{"trials":358,"activeCount":70},[],{"trials":360,"activeCount":70},[361],{"nctId":362,"briefTitle":363,"status":215,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":374},"NCT03674606","Trial of Early Screening Test for Pre-eclampsia and Growth Restriction",[62],"2016-04-13","2014-02-01",546,[369,370,371,372,373],"Pre-Eclampsia","Placenta Diseases","Eclampsia Preeclampsia","Fetal Growth Retardation","Foetal Growth Restriction",[349],{"trials":376,"activeCount":70},[],{"intervention":224,"totalTrials":99,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":393},{"trials":380,"activeCount":70},[],{"trials":382,"activeCount":70},[],{"trials":384,"activeCount":70},[],{"trials":386,"activeCount":70},[],{"trials":388,"activeCount":70},[389],{"nctId":213,"briefTitle":214,"status":215,"phases":390,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":391,"interventions":392},[62],[221,222],[224,189],{"trials":394,"activeCount":70},[],{"intervention":396,"totalTrials":99,"cells":397},"Fentanyl Citrate",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":419},{"trials":399,"activeCount":70},[],{"trials":401,"activeCount":70},[],{"trials":403,"activeCount":70},[],{"trials":405,"activeCount":70},[],{"trials":407,"activeCount":70},[408],{"nctId":409,"briefTitle":410,"status":215,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT03682211","Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children",[62],"2013-11-14","2012-12-12",31,[30,416],"Sickle Cell Disease",[396,418],"Morphine sulphate",{"trials":420,"activeCount":70},[],{"intervention":418,"totalTrials":99,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":437},{"trials":424,"activeCount":70},[],{"trials":426,"activeCount":70},[],{"trials":428,"activeCount":70},[],{"trials":430,"activeCount":70},[],{"trials":432,"activeCount":70},[433],{"nctId":409,"briefTitle":410,"status":215,"phases":434,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":435,"interventions":436},[62],[30,416],[396,418],{"trials":438,"activeCount":70},[],{"intervention":440,"totalTrials":99,"cells":441},"Naloxone",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":461},{"trials":443,"activeCount":70},[],{"trials":445,"activeCount":70},[],{"trials":447,"activeCount":70},[],{"trials":449,"activeCount":70},[],{"trials":451,"activeCount":70},[452],{"nctId":453,"briefTitle":454,"status":215,"phases":455,"primaryCompletion":204,"completion":204,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT02885948","The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.",[62],"2016-04",96,[459],"Respiratory Depression",[440],{"trials":462,"activeCount":70},[],{"intervention":464,"totalTrials":99,"cells":465},"Colchicine",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":485,"NA":487},{"trials":467,"activeCount":70},[],{"trials":469,"activeCount":70},[],{"trials":471,"activeCount":70},[],{"trials":473,"activeCount":70},[474],{"nctId":475,"briefTitle":476,"status":215,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":484},"NCT02898610","Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke",[61],"2024-01-31","2016-12-12",3154,[482,483],"Ischemic Attack, Transient","Stroke",[464],{"trials":486,"activeCount":70},[],{"trials":488,"activeCount":70},[],{"intervention":490,"totalTrials":66,"cells":491},"Sitagliptin",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":493,"activeCount":70},[],{"trials":495,"activeCount":70},[],{"trials":497,"activeCount":70},[498,508],{"nctId":499,"briefTitle":500,"status":215,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT02347501","Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)",[60],"2016-12","2013-11",118,[506],"Psoriasis",[490],{"nctId":509,"briefTitle":510,"status":215,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":517},"NCT01991197","Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.",[60],"2016-01","2014-04",20,[506,516],"Type 2 Diabetes Mellitus",[490,518,519,520],"Gliclazide","Sitagliptin matched placebo","Gliclazide matched placebo",{"trials":522,"activeCount":70},[],{"trials":524,"activeCount":70},[],{"trials":526,"activeCount":70},[],{"intervention":528,"totalTrials":99,"cells":529},"Citalopram +\u002F- Gabapentin + Sleepio + support person",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":531,"activeCount":70},[],{"trials":533,"activeCount":70},[],{"trials":535,"activeCount":70},[536],{"nctId":537,"briefTitle":538,"status":215,"phases":539,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":547},"NCT04766229","The Menopause After Cancer Study",[60],"2022-11-30","2021-06-21",205,[544,545,546],"Menopause","Cancer","Insomnia",[528],{"trials":549,"activeCount":70},[],{"trials":551,"activeCount":70},[],{"trials":553,"activeCount":70},[],{"intervention":518,"totalTrials":99,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":557,"activeCount":70},[],{"trials":559,"activeCount":70},[],{"trials":561,"activeCount":70},[562],{"nctId":509,"briefTitle":510,"status":215,"phases":563,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":564,"interventions":565},[60],[506,516],[490,518,519,520],{"trials":567,"activeCount":70},[],{"trials":569,"activeCount":70},[],{"trials":571,"activeCount":70},[],{"intervention":519,"totalTrials":99,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":575,"activeCount":70},[],{"trials":577,"activeCount":70},[],{"trials":579,"activeCount":70},[580],{"nctId":509,"briefTitle":510,"status":215,"phases":581,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":582,"interventions":583},[60],[506,516],[490,518,519,520],{"trials":585,"activeCount":70},[],{"trials":587,"activeCount":70},[],{"trials":589,"activeCount":70},[],{"intervention":520,"totalTrials":99,"cells":591},{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":593,"activeCount":70},[],{"trials":595,"activeCount":70},[],{"trials":597,"activeCount":70},[598],{"nctId":509,"briefTitle":510,"status":215,"phases":599,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":600,"interventions":601},[60],[506,516],[490,518,519,520],{"trials":603,"activeCount":70},[],{"trials":605,"activeCount":70},[],{"trials":607,"activeCount":70},[],{"intervention":609,"totalTrials":99,"cells":610},"Colchicine 0.5 MG",{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":612,"activeCount":70},[],{"trials":614,"activeCount":70},[],{"trials":616,"activeCount":70},[617],{"nctId":618,"briefTitle":619,"status":202,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":628},"NCT06062277","COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE)",[60],"2024-10","2025-06","2023-10",91,[626,627],"Ischemic Stroke","Atherosclerosis",[609],{"trials":630,"activeCount":70},[],{"trials":632,"activeCount":70},[],{"trials":634,"activeCount":70},[],{"intervention":636,"totalTrials":99,"cells":637},"Octreotide",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":639,"activeCount":70},[],{"trials":641,"activeCount":70},[],{"trials":643,"activeCount":70},[],{"trials":645,"activeCount":70},[],{"trials":647,"activeCount":70},[],{"trials":649,"activeCount":70},[650],{"nctId":651,"briefTitle":652,"status":215,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT02010385","Investigation of the Effects of Obesity Surgery on Appetitive Behaviour",[63],"2018-06","2013-02",30,[658],"Roux-en-Y Bariatric Surgery",[636,660],"Saline",{"intervention":660,"totalTrials":99,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":664,"activeCount":70},[],{"trials":666,"activeCount":70},[],{"trials":668,"activeCount":70},[],{"trials":670,"activeCount":70},[],{"trials":672,"activeCount":70},[],{"trials":674,"activeCount":70},[675],{"nctId":651,"briefTitle":652,"status":215,"phases":676,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":677,"interventions":678},[63],[658],[636,660],{"intervention":680,"totalTrials":99,"cells":681},"Dipeptidyl-Peptidase IV Inhibitors",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":683,"activeCount":70},[],{"trials":685,"activeCount":70},[],{"trials":687,"activeCount":70},[],{"trials":689,"activeCount":70},[],{"trials":691,"activeCount":70},[],{"trials":693,"activeCount":70},[694],{"nctId":695,"briefTitle":696,"status":215,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":704},"NCT02150707","The Differential Effects of Diabetes Therapy on Inflammation",[],"2015-12","2014-05",17,[702,703],"Diabetic Nephropathy","Type 2 Diabetes",[680,705],"Glucagon-Like Peptide 1",{"intervention":705,"totalTrials":99,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":709,"activeCount":70},[],{"trials":711,"activeCount":70},[],{"trials":713,"activeCount":70},[],{"trials":715,"activeCount":70},[],{"trials":717,"activeCount":70},[],{"trials":719,"activeCount":70},[720],{"nctId":695,"briefTitle":696,"status":215,"phases":721,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":722,"interventions":723},[],[702,703],[680,705]]